Role of itraconazole in haematology/oncology
Open Access
- 1 March 2003
- journal article
- review article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 88 (3) , 258-260
- https://doi.org/10.1136/adc.88.3.258
Abstract
The antifungal agents most frequently used in prophylaxis and treatment are amphotericin B (and its new lipid forms) and azoles such as fluconazole, itraconazole, and more recently voriconazole. This review assesses the role of itraconazole in paediatric haematology/oncology practice. Its broader spectrum of activity and availability in oral and intravenous forms allow a flexible approach in the management of fungal infections.Keywords
This publication has 28 references indexed in Scilit:
- Itraconazole Oral Solution for Primary Prophylaxis of Fungal Infections in Patients with Hematological Malignancy and Profound Neutropenia: a Randomized, Double-Blind, Double-Placebo, Multicenter Trial Comparing Itraconazole and Amphotericin BAntimicrobial Agents and Chemotherapy, 2000
- A Double-Blind, Randomized, Placebo-Controlled Trial of Itraconazole Capsules as Antifungal Prophylaxis for Neutropenic PatientsClinical Infectious Diseases, 2000
- The child with cancer and infection. II. Nonbacterial infectionsThe Journal of Pediatrics, 1991
- Fungal infections in bone marrow transplant patients.1990
- Antifungal Prophylaxis with Itraconazole in Prolonged Neutropenia: Correlation with Plasma LevelsMycoses, 1989
- The Clinical Pharmacokinetics of Itraconazole: An OverviewMycoses, 1989
- The effects of food and dose on the oral systemic availability of itraconazole in healthy subjectsEuropean Journal of Clinical Pharmacology, 1989
- ItraconazoleDrugs, 1989
- Itraconazole pharmacokinetics in patients with renal dysfunctionAntimicrobial Agents and Chemotherapy, 1988
- Infection in cancer patients: A continuing associationThe American Journal of Medicine, 1986